Dificid (fidaxomicin) Clinical Trials Ongoing In Pediatric Patients Diagnosed With CDAD

Cubist Logo 300dpi

Clinical Trials:

DIFICID (fidaxomicin) is currently FDA approved to treat Clostridium difficile-associated diarrhea (CDAD) in adult patients 18 years of age and older.

http://www.dificid.com

 

Currently, clinical trials are ongoing to assess the efficacy and safety of DIFICID, in either a tablet and oral suspension formulation, in pediatric patients with CDAD.

In addition, DIFICID is currently in clinical trials to determine the efficacy of use as a prophylaxis against CDAD in adult patients undergoing hematopoietic stem cell transplantation (HSCT).

 

*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.